Ventavis

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

iloprost

Available from:

Bayer AG

ATC code:

B01AC11

INN (International Name):

iloprost

Therapeutic group:

Aġenti antitrombotiċi

Therapeutic area:

Pressjoni għolja, pulmonari

Therapeutic indications:

Kura ta 'pazjenti bi pressjoni għolja pulmonari primarja, ikklassifikata bħala klassi funzjonali III ta' Assoċjazzjoni tal-Qalb ta 'New York, biex ittejjeb il-kapaċità u s-sintomi ta' eżerċizzju.

Product summary:

Revision: 30

Authorization status:

Awtorizzat

Authorization date:

2003-09-15

Patient Information leaflet

                                43
B. FULJETT TA’ TAGĦRIF
44
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-UTENT
VENTAVIS 10 MIKROGRAMMI/ML SOLUZZJONI GĦAN-NEBULIZZATUR
Iloprost
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TUŻA DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib, lill-ispiżjar jew
lill-infermier tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara, anke jekk għandhom l-istess sinjali ta’
mard bħal tiegħek.
-
Jekk ikollok xi effett sekondarju kellem lit-tabib, lill-ispiżjar jew
lill-infermier tiegħek. Dan
jinkludi xi effett sekondarju possibbli li mhuwiex elenkat f’dan
il-fuljett. Ara sezzjoni 4.
F’DAN IL-FULJETT
1.
X’inhu Ventavis u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tuża Ventavis
3.
Kif għandek tuża Ventavis
4.
Effetti sekondarji possibbli
5.
Kif taħżen Ventavis
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU VENTAVIS U GЋALXIEX JINTUŻA
X’INHU VENTAVIS
Is-sustanza attiva ta’ Ventavis hija iloporst. Din timita sustanza
naturali fil-ġisem li tissejjaħ
prostacycline. Ventavis jinibixxi bblukkar jew tidjiq mhux mixtieq
ta’ kanali tad-demm u jħalli iktar
demm jgħaddi minn ġol-kanali.
GĦALXIEX JINTUŻA VENTAVIS
Ventavis jintuża biex jittratta każijiet moderati ta’ pressjoni
pulmonari għolja primarja (PPH
_primary _
_pulmonary hypertension_
) f’pazjenti adulti. PPH hija kategorija ta’ pressjoni pulmonari
għolja fejn il-
kawża tal-pressjoni għolja mhix magħrufa.
Din hija kondizzjoni fejn il-pressjoni fil-kanali tad-demm ta’ bejn
il-qalb u l-pulmun hija għolja wisq.
Ventavis jintuża biex itejjeb il-kapaċità li wieħed jagħmel
eżerċizzju (il-ħila li twettaq attività fiżika)
u s-sintomi.
KIF JAĦDEM VENTAVIS
Meta tiġbed iċ-ċpar man-nifs, iwassal Ventavis fil-pulmun, fejn
ikun jista’ jaħdem bl-aktar mod
effettiv fl-arterja ta’ bejn il-qal
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Ventavis 10 mikrogrammi/ml soluzzjoni għan-nebulizzatur
Ventavis 20 mikrogramma/ml soluzzjoni għan-nebulizzatur
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Ventavis 10 mikrogrammi/ml soluzzjoni għan-nebulizzatur
Soluzzjoni ta’ 1 ml fiha 10 mikrogrammi ta’ iloprost (bħala
iloprost trometamol).
Kull ampulla b’soluzzjoni ta’ 1 ml fiha 10 mikrogrammi ta’
iloprost.
Kull ampulla b’soluzzjoni ta’ 2 ml fiha 20 mikrogramma ta’
iloprost.
Ventavis 20 mikrogramma/ml soluzzjoni għan-nebulizzatur
Soluzzjoni ta’ 1 ml fiha 20 mikrogramma ta’ iloprost (bħala
iloprost trometamol).
Kull ampulla b’soluzzjoni ta’ 1 ml fiha 20 mikrogramma ta’
iloprost.
Eċċipjent b’effett magħruf
•
Ventavis 10 mikrogrammi/ml:
Kull ml fih 0.81 mg ta’ 96% ethanol (ekwivalenti għal 0.75 mg
ethanol)
•
Ventavis 20 mikrogramma/ml:
Kull ml fih 1.62 mg ta’ 96% ethanol (ekwivalenti għal 1.50 mg
ethanol).
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Soluzzjoni għan-nebulizzatur.
Ventavis 10 mikrogrammi/ml soluzzjoni għan-nebulizzatur
Soluzzjoni ċara u mingħajr kulur.
Ventavis 20 mikrogramma/ml soluzzjoni għan-nebulizzatur
Soluzzjoni ċara u mingħajr kulur sa ftit safranija.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Trattament ta’ pazjenti adulti bi pressjoni pulmonari għolja
primarja, ikklassifikata bħala klassi
funzjonali III ta’ NYHA, biex itejjeb il-kapaċità ta’
l-eżerċizzju u s-sintomi.
4.2
POŻOLOĠIJA U METODU TA’ KIF GĦANDU JINGĦATA
PRODOTT MEDIĊINALI
APPARAT ADATTAT GĦAT-TEĦID MAN-NIFS (NEBULIZZATUR) LI
GĦANDU JINTUŻA
Ventavis
10 mikrogrammi/ml
Breelib
I-Neb AAD
Venta-Neb
Ventavis
20 mikrogramma/ml
Breelib
I-Neb AAD
Ventavis għandu jinbeda biss u jiġi mmonitorjat minn tabib li
għandu esperjenza fit-trattament ta’
pressjoni pulmonari għolja.
3
Pożoloġija
_Doża għal kull sessjoni ta’ teħid man-nifs _
Fil-bidu tat-trattament b’Ventavis l-eww
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 30-11-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 30-11-2023
Public Assessment Report Public Assessment Report Bulgarian 07-02-2014
Patient Information leaflet Patient Information leaflet Spanish 30-11-2023
Public Assessment Report Public Assessment Report Spanish 07-02-2014
Patient Information leaflet Patient Information leaflet Czech 30-11-2023
Public Assessment Report Public Assessment Report Czech 07-02-2014
Patient Information leaflet Patient Information leaflet Danish 30-11-2023
Public Assessment Report Public Assessment Report Danish 07-02-2014
Patient Information leaflet Patient Information leaflet German 30-11-2023
Public Assessment Report Public Assessment Report German 07-02-2014
Patient Information leaflet Patient Information leaflet Estonian 30-11-2023
Public Assessment Report Public Assessment Report Estonian 07-02-2014
Patient Information leaflet Patient Information leaflet Greek 30-11-2023
Public Assessment Report Public Assessment Report Greek 07-02-2014
Patient Information leaflet Patient Information leaflet English 30-11-2023
Public Assessment Report Public Assessment Report English 07-02-2014
Patient Information leaflet Patient Information leaflet French 30-11-2023
Public Assessment Report Public Assessment Report French 07-02-2014
Patient Information leaflet Patient Information leaflet Italian 30-11-2023
Public Assessment Report Public Assessment Report Italian 07-02-2014
Patient Information leaflet Patient Information leaflet Latvian 30-11-2023
Public Assessment Report Public Assessment Report Latvian 07-02-2014
Patient Information leaflet Patient Information leaflet Lithuanian 30-11-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 30-11-2023
Public Assessment Report Public Assessment Report Lithuanian 07-02-2014
Patient Information leaflet Patient Information leaflet Hungarian 30-11-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 30-11-2023
Public Assessment Report Public Assessment Report Hungarian 07-02-2014
Patient Information leaflet Patient Information leaflet Dutch 30-11-2023
Public Assessment Report Public Assessment Report Dutch 07-02-2014
Patient Information leaflet Patient Information leaflet Polish 30-11-2023
Public Assessment Report Public Assessment Report Polish 07-02-2014
Patient Information leaflet Patient Information leaflet Portuguese 30-11-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 30-11-2023
Public Assessment Report Public Assessment Report Portuguese 07-02-2014
Patient Information leaflet Patient Information leaflet Romanian 30-11-2023
Public Assessment Report Public Assessment Report Romanian 07-02-2014
Patient Information leaflet Patient Information leaflet Slovak 30-11-2023
Public Assessment Report Public Assessment Report Slovak 07-02-2014
Patient Information leaflet Patient Information leaflet Slovenian 30-11-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 30-11-2023
Public Assessment Report Public Assessment Report Slovenian 07-02-2014
Patient Information leaflet Patient Information leaflet Finnish 30-11-2023
Public Assessment Report Public Assessment Report Finnish 07-02-2014
Patient Information leaflet Patient Information leaflet Swedish 30-11-2023
Public Assessment Report Public Assessment Report Swedish 07-02-2014
Patient Information leaflet Patient Information leaflet Norwegian 30-11-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 30-11-2023
Patient Information leaflet Patient Information leaflet Icelandic 30-11-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 30-11-2023
Patient Information leaflet Patient Information leaflet Croatian 30-11-2023
Public Assessment Report Public Assessment Report Croatian 07-02-2014

Search alerts related to this product

View documents history